Millennium Management LLC Decreases Stock Holdings in Vaxart, Inc. (NASDAQ:VXRT)

Millennium Management LLC trimmed its holdings in Vaxart, Inc. (NASDAQ:VXRT) by 24.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,990,642 shares of the biotechnology company’s stock after selling 978,449 shares during the quarter. Millennium Management LLC owned about 1.31% of Vaxart worth $1,980,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Bank of America Corp DE raised its position in shares of Vaxart by 10.8% during the 4th quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 17,942 shares during the period. Invesco Ltd. raised its position in Vaxart by 48.6% in the fourth quarter. Invesco Ltd. now owns 75,798 shares of the biotechnology company’s stock valued at $50,000 after purchasing an additional 24,803 shares during the period. Graham Capital Management L.P. raised its position in Vaxart by 155.8% in the fourth quarter. Graham Capital Management L.P. now owns 53,331 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 32,482 shares during the period. Sequoia Financial Advisors LLC raised its position in Vaxart by 140.9% in the fourth quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 35,213 shares during the period. Finally, Geode Capital Management LLC raised its position in Vaxart by 2.3% in the fourth quarter. Geode Capital Management LLC now owns 2,601,139 shares of the biotechnology company’s stock valued at $1,723,000 after purchasing an additional 57,911 shares during the period. 18.05% of the stock is owned by hedge funds and other institutional investors.

Vaxart Stock Up 3.9%

NASDAQ:VXRT opened at $0.45 on Tuesday. The company has a fifty day simple moving average of $0.40 and a two-hundred day simple moving average of $0.56. The company has a market cap of $102.70 million, a price-to-earnings ratio of -1.10 and a beta of 1.27. Vaxart, Inc. has a 52 week low of $0.29 and a 52 week high of $1.07.

Vaxart (NASDAQ:VXRT) last posted its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The business had revenue of $20.88 million during the quarter, compared to the consensus estimate of $2.85 million. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%. On average, analysts expect that Vaxart, Inc. will post -0.39 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on VXRT shares. B. Riley cut their target price on Vaxart from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Thursday, March 27th. Wall Street Zen upgraded shares of Vaxart to a “hold” rating in a research note on Thursday, May 22nd.

Insider Buying and Selling

In other news, insider Steven Lo bought 100,000 shares of the stock in a transaction that occurred on Monday, May 19th. The stock was purchased at an average price of $0.49 per share, for a total transaction of $49,000.00. Following the completion of the purchase, the insider now owns 100,000 shares in the company, valued at approximately $49,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 2.90% of the company’s stock.

Vaxart Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.